J Korean Soc Transplant.  2013 Jun;27(2):37-41.

The Management of HCV Recurrence after Liver Transplantation

• Choi Y
• Lee KW

Abstract

Liver transplantation (LT) for hepatitis C virus (HCV)-related liver diseases has been increasing in Korea. HCV recurrence, a serious complication after LT, can accelerate liver cirrhosis and fatal graft loss. Therefore, the prevention and appropriate treatment for HCV recurrence can improve a LT patient's quality of life and survival. In considering the relationship between immunosuppressants and HCV recurrence, there is no clear difference in HCV recurrence between the immunosuppressant tacrolimus or cyclosporine, and the use of steroids for patients with HCV is still under debate. In the management of HCV recurrence, direct-acting antivirals, such as protease inhibitors, polymerase inhibitors, or other nonstructural protein inhibitors will open a new era in HCV treatment. However, their safety and drug interactions with immunosuppressants should be evaluated for patients after LT.

Keyword

HCV; Immunosuppression; Liver transplantation

MeSH Terms

Antiviral Agents
Cyclosporine
Drug Interactions
Hepacivirus
Humans
Immunosuppression
Immunosuppressive Agents
Korea
Liver
Liver Cirrhosis
Liver Diseases
Liver Transplantation
Protease Inhibitors
Quality of Life
Recurrence
Steroids
Tacrolimus
Transplants
Antiviral Agents
Cyclosporine
Immunosuppressive Agents
Protease Inhibitors
Steroids
Tacrolimus

Reference

1). Prieto M, Berenguer M, Rimola A, Loinaz C, Barrios C, Clemente G, et al. Liver transplantation in hepatitis C. A Spanish multi-centre experience. Eur J Gastroenterol Hepatol. 1998; 10:771–6.

2). Lee HW, Lee KW, Kim BW, Song GW, Han YS, Kwon CH, et al. Liver transplantation for hepatitis C virus-re-lated liver disease in Korea. J Korean Soc Transplant. 2012; 26:269–76.

3). Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122:889–96.

4). Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999; 29:250–6.

5). Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009; 9:1707–13.

6). Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996; 110:167–77.

7). Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004; 77:226–31.

8). Lladó L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl. 2008; 14:1752–60.

9). Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation. 2007; 84:829–35.

10). Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for antihepatitis C virus strategy. Rev Med Virol. 2007; 17:245–52.

11). Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003; 38:1282–8.

12). Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila- Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sus-tained virological response after liver transplantation. Liver Transpl. 2006; 12:51–7.

13). McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006; 6:1578–85.

14). Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant. 2010; 15:301–9.

15). Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009; 88:1214–21.

16). Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation. 2006; 82:579–80.

17). Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with mi-croemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 1998; 65:1044–6.

18). Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004; 10:1258–62.

19). Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, López-Andujar R, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation. 2010; 90:1204–9.

20). Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006(4):CD005161.

21). Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012; 56:973–83.

22). Mannová P, Beretta L. Activation of the N-Ras-PI3K- Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol. 2005; 79:8742–9.

23). Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, Fahrleitner-Pammer A, et al. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol. 2010; 10:990–3.

24). Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010; 51:1237–43.

25). Filipponi F, Salizzoni M, Grazi G, Pisati R, Ferrara R. Study of simulect-based, steroid-free immunosuppressive regimen in HCV+ de novo liver transplant patients: pre-liminary results. Transplant Proc. 2001; 33:3211–2.

26). Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl. 2007; 13:1521–31.

27). Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008; 8:2426–33.

28). Charlton M, Seaberg E, Wiesner R, Everhart J, Zetter-man R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998; 28:823–30.

29). Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005; 41:289–98.

30). Ho JK, Harrigan PR, Sherlock CH, Steinbrecher UP, Erb SR, Mo T, et al. Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation. 2006; 81:129–31.

31). Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461:399–401.

32). Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011; 53:317–24.

33). Coilly A, Furlan V, Roche B, Barau C, Noël C, Bonhomme-Faivre L, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012; 56:5728–34.

34). Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al. Multicenter experience using te-laprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl [in press 2013 May 21].